T790M
· 9 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | T790M | “DISCUSSION: TGTKIs selectively target mutant EGFR to overcome the resistant mutation T790M, a major clinical challenge against first- and second-generation TKIs.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “Secondary mutations (e.g. 'T790M', 'C797S'), off-target effects, and resistance due to alternate pathway activation reduce the efficacy of currently available EGFR inhibitors.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “For each class, we highlight lead compounds that achieved sub-nanomolar to low-micromolar EGFR inhibition, delineate substituent effects on kinase affinity and cellular antiproliferative activity, and discuss strategies to overcome common resistance mutations (e.g., L858R, T790M, C797S).” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “Biological evaluation of the retrieved hit compounds showed suppressing activity against EGFR auto phosphorylation and selective apoptosis-induced effects toward lung cancer cells harboring the EGFR L858R/T790M double mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “Non-small-cell lung cancer (NSCLC) with a gene mutation that encodes EGFR is sensitive to approved EGFR inhibitors, but usually resistance develops, which is frequently mediated by T790M EGFR mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “This novel irreversible mutant-selective EGFR inhibitor targets EGFR containing both the resistance mutation (T790M) and the activating mutations (L858R and Del19), while it does not affect wild-type EGFR.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “NQT was found to be more effective than osimertinib against the EGFR L858R plus T790M mutation (L858R+T790M).” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “However, treatment with both first- and second-generation TKIs results in acquired resistance and is related to various toxicities; the EGFR T790M mutation has been associated with this resistance.” | 0.82 | literature_variant_regex_v2 |
| variant | T790M | “In May 2016, OTB was approved in South Korea for the treatment of patients suffering from metastatic or locally advanced EGFR T790M mutation-positive NSCLC.” | 0.82 | literature_variant_regex_v2 |